UNCY - The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
(NewsDirect)
By Julian Richard, Benzinga
UnicyciveTherapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical companycommitted to developing effective and safe treatments for kidney(renal) disease to reduce death rates and improve patients and theircaregivers' quality of life by combining cutting-edge researchwith innovative products and services, Unicycive Therapeutics Inc.works toward providing transformative treatments to fight acute andchronic diseases.
Through itsgroundbreaking research and innovative treatments, UnicyciveTherapeutics is spearheading the charge to bring renewed hope tocountless patients worldwide. Two lead compoundsare the subject of clinical development: Renazorb™. aninvestigational treatment for increased phosphorus in the blood(hyperphosphatemia) in those with chronic kidney disease (CKD) ondialysis, and UNI-494, for the treatment of acute kidneyinjury.
Silent And Insidious
Chronic kidney disease is a serious,life-threatening condition that affects countless people worldwide. Ithas emerged as one of the leadingcauses of death globally and is one of only a handful ofnon-communicable diseases to have i ncreased mortality over the past two decades. Unfortunately, kidney diseaseoften goes undetected until there is significant kidney damage, resulting in end-stage renaldisease and death. This makes it all the more important for patientsand their carers to understand this silent killer's signs,symptoms and consequences.
The disease can be debilitating and havedevastating effects on those affected. Consequently, CDK causes aprofound decreasein the quality of life of patients. Patients suffering fromadvanced CKD may experience fatigue, nausea, swelling in the hands and feet, high blood pressure,changes in urine color or amount and a build-up of toxins in the blood(uremia). In severe cases, these symptoms can lead to an inability towork or function normally, which can cause further physical andemotional stress.
In addition to the physical, emotional and financial impact ofkidney disease, there is also a socialimpact. Those suffering from kidney disease may be unable toparticipate in activities they once enjoyed due to fatigue or othersymptoms. They may also find it challenging to interact socially withfriends and family because of their condition and lowself-esteem.
Forcaregivers of those suffering from kidney disease, the impact canprofoundly affect their physical andemotional well-being . They may be required to manage physicaland emotional symptoms that are difficult to understand or predict andmanage treatments ranging from dialysis to dietary changes. Caregiversmust also understand medication regimens and any potential sideeffects to ensure their loved one's safety while managing thecondition.
Thoseaffected by CKD and their caregivers must understand the seriousnessof this condition to take steps towards preventing it, managing iteffectively, and finding support if needed. Awareness of the signs andsymptoms of kidney disease can help patients identify the issue beforedamage occurs, while access to treatments can ensure thatcomplications are prevented or managed appropriately.
Visit https://unicycive.com formore information on the company and its product candidates.
This article was originally published onBenzinga here .
UnicyciveTherapeutics is a biotechnology company developing novel treatmentsfor kidney diseases. Unicycive’s lead drug, Renazorb, is a novelphosphate binding agent being developed for the treatment ofhyperphosphatemia. UNI-494 is a patent-protected new chemical entityin late preclinical development for the treatment of acute kidneyinjury.
This post contains sponsored advertising content.This content is for informational purposes only and is not intended tobe investing advice.
Contact Details
AnneMarie Fields - Stern Investor Relations
+1 212-362-1200
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.